1
|
Sevinc Ozdemir N, Belyaev D, Castro MN, Balakin S, Opitz J, Wihadmadyatami H, Anggraeni R, Yucel D, Kenar H, Beshchasna N, Ana ID, Hasirci V. Advances in In Vitro Blood-Air Barrier Models and the Use of Nanoparticles in COVID-19 Research. TISSUE ENGINEERING. PART B, REVIEWS 2024; 30:82-96. [PMID: 37597193 DOI: 10.1089/ten.teb.2023.0117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/21/2023]
Abstract
Respiratory infections caused by coronaviruses (CoVs) have become a major public health concern in the past two decades as revealed by the emergence of SARS-CoV in 2002, MERS-CoV in 2012, and SARS-CoV-2 in 2019. The most severe clinical phenotypes commonly arise from exacerbation of immune response following the infection of alveolar epithelial cells localized at the pulmonary blood-air barrier. Preclinical rodent models do not adequately represent the essential genetic properties of the barrier, thus necessitating the use of humanized transgenic models. However, existing monolayer cell culture models have so far been unable to mimic the complex lung microenvironment. In this respect, air-liquid interface models, tissue engineered models, and organ-on-a-chip systems, which aim to better imitate the infection site microenvironment and microphysiology, are being developed to replace the commonly used monolayer cell culture models, and their use is becoming more widespread every day. On the contrary, studies on the development of nanoparticles (NPs) that mimic respiratory viruses, and those NPs used in therapy are progressing rapidly. The first part of this review describes in vitro models that mimic the blood-air barrier, the tissue interface that plays a central role in COVID-19 progression. In the second part of the review, NPs mimicking the virus and/or designed to carry therapeutic agents are explained and exemplified.
Collapse
Affiliation(s)
- Neval Sevinc Ozdemir
- Acibadem University (ACU) Biomaterials A&R Center, Atasehir, Istanbul, Turkey
- Department of Medical Biotechnology, ACU Graduate School of Health Sciences, Istanbul, Turkey
- ACU Department of Pharmaceutical Basic Sciences, School of Pharmacy, Istanbul, Turkey
| | - Dmitry Belyaev
- Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche Straße 2, Dresden, Germany
| | - Manuel Nieto Castro
- Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche Straße 2, Dresden, Germany
| | - Sascha Balakin
- Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche Straße 2, Dresden, Germany
| | - Joerg Opitz
- Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche Straße 2, Dresden, Germany
| | - Hevi Wihadmadyatami
- Department of Tissue Engineering and Regenerative Medicine, Research Collaboration Center for Biomedical Scaffolds, National Research and Innovation Agency (BRIN) and Universitas Gadjah Mada (UGM), Bulaksumur, Yogyakarta, Indonesia
- Department of Anatomy, Faculty of Veterinary Medicine, Universitas Gadjah Mada (UGM), Bulaksumur, Yogyakarta, Indonesia
| | - Rahmi Anggraeni
- Department of Tissue Engineering and Regenerative Medicine, Research Collaboration Center for Biomedical Scaffolds, National Research and Innovation Agency (BRIN) and Universitas Gadjah Mada (UGM), Bulaksumur, Yogyakarta, Indonesia
| | - Deniz Yucel
- Acibadem University (ACU) Biomaterials A&R Center, Atasehir, Istanbul, Turkey
- ACU Graduate Department of Biomaterials, Istanbul, Turkey
- Department of Histology and Embryology, ACU School of Medicine, Istanbul, Turkey
| | - Halime Kenar
- Acibadem University (ACU) Biomaterials A&R Center, Atasehir, Istanbul, Turkey
- ACU Graduate Department of Biomaterials, Istanbul, Turkey
- ACU Faculty of Engineering Sciences, Department of Biomedical Engineering, Istanbul, Turkey
| | - Natalia Beshchasna
- Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche Straße 2, Dresden, Germany
| | - Ika Dewi Ana
- Department of Tissue Engineering and Regenerative Medicine, Research Collaboration Center for Biomedical Scaffolds, National Research and Innovation Agency (BRIN) and Universitas Gadjah Mada (UGM), Bulaksumur, Yogyakarta, Indonesia
- Department of Dental Biomedical Sciences, Faculty of Dentistry, Universitas Gadjah Mada (UGM), Bulaksumur, Yogyakarta, Indonesia
| | - Vasif Hasirci
- Acibadem University (ACU) Biomaterials A&R Center, Atasehir, Istanbul, Turkey
- ACU Graduate Department of Biomaterials, Istanbul, Turkey
- ACU Faculty of Engineering Sciences, Department of Biomedical Engineering, Istanbul, Turkey
- BIOMATEN, METU Ctr. of Excellence in Biomaterials and Tissue Engineering, Ankara, Turkey
| |
Collapse
|
2
|
Liu S, Hu M, Liu X, Liu X, Chen T, Zhu Y, Liang T, Xiao S, Li P, Ma X. Nanoparticles and Antiviral Vaccines. Vaccines (Basel) 2023; 12:30. [PMID: 38250843 PMCID: PMC10819235 DOI: 10.3390/vaccines12010030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 12/19/2023] [Accepted: 12/22/2023] [Indexed: 01/23/2024] Open
Abstract
Viruses have threatened human lives for decades, causing both chronic and acute infections accompanied by mild to severe symptoms. During the long journey of confrontation, humans have developed intricate immune systems to combat viral infections. In parallel, vaccines are invented and administrated to induce strong protective immunity while generating few adverse effects. With advancements in biochemistry and biophysics, different kinds of vaccines in versatile forms have been utilized to prevent virus infections, although the safety and effectiveness of these vaccines are diverse from each other. In this review, we first listed and described major pathogenic viruses and their pandemics that emerged in the past two centuries. Furthermore, we summarized the distinctive characteristics of different antiviral vaccines and adjuvants. Subsequently, in the main body, we reviewed recent advances of nanoparticles in the development of next-generation vaccines against influenza viruses, coronaviruses, HIV, hepatitis viruses, and many others. Specifically, we described applications of self-assembling protein polymers, virus-like particles, nano-carriers, and nano-adjuvants in antiviral vaccines. We also discussed the therapeutic potential of nanoparticles in developing safe and effective mucosal vaccines. Nanoparticle techniques could be promising platforms for developing broad-spectrum, preventive, or therapeutic antiviral vaccines.
Collapse
Affiliation(s)
- Sen Liu
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China; (S.L.); (M.H.); (X.L.); (X.L.); (T.C.); (Y.Z.); (T.L.); (S.X.); (P.L.)
- School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China
| | - Meilin Hu
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China; (S.L.); (M.H.); (X.L.); (X.L.); (T.C.); (Y.Z.); (T.L.); (S.X.); (P.L.)
- State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou 511400, China
| | - Xiaoqing Liu
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China; (S.L.); (M.H.); (X.L.); (X.L.); (T.C.); (Y.Z.); (T.L.); (S.X.); (P.L.)
- Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, China
| | - Xingyu Liu
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China; (S.L.); (M.H.); (X.L.); (X.L.); (T.C.); (Y.Z.); (T.L.); (S.X.); (P.L.)
| | - Tao Chen
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China; (S.L.); (M.H.); (X.L.); (X.L.); (T.C.); (Y.Z.); (T.L.); (S.X.); (P.L.)
- State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou 511400, China
| | - Yiqiang Zhu
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China; (S.L.); (M.H.); (X.L.); (X.L.); (T.C.); (Y.Z.); (T.L.); (S.X.); (P.L.)
| | - Taizhen Liang
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China; (S.L.); (M.H.); (X.L.); (X.L.); (T.C.); (Y.Z.); (T.L.); (S.X.); (P.L.)
- State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou 511400, China
| | - Shiqi Xiao
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China; (S.L.); (M.H.); (X.L.); (X.L.); (T.C.); (Y.Z.); (T.L.); (S.X.); (P.L.)
| | - Peiwen Li
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China; (S.L.); (M.H.); (X.L.); (X.L.); (T.C.); (Y.Z.); (T.L.); (S.X.); (P.L.)
| | - Xiancai Ma
- Guangzhou National Laboratory, Guangzhou International Bio-Island, Guangzhou 510005, China; (S.L.); (M.H.); (X.L.); (X.L.); (T.C.); (Y.Z.); (T.L.); (S.X.); (P.L.)
- School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China
- State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou 511400, China
- Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, China
| |
Collapse
|
3
|
Wei-Wen Hsiao W, Fadhilah G, Lee CC, Endo R, Lin YJ, Angela S, Ku CC, Chang HC, Chiang WH. Nanomaterial-based biosensors for avian influenza virus: A new way forward. Talanta 2023; 265:124892. [PMID: 37451119 DOI: 10.1016/j.talanta.2023.124892] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2023] [Revised: 06/23/2023] [Accepted: 06/30/2023] [Indexed: 07/18/2023]
Abstract
Avian influenza virus (AIV) is a zoonotic virus that can be transmitted from animals to humans. Although human infections are rare, the virus has a high mortality rate when contracted. Appropriate detection methods are thus crucial for combatting this pathogen. There is a growing demand for rapid, selective, and accurate methods of identifying the virus. Numerous biosensors have been designed and commercialized to detect AIV. However, they all have considerable shortcomings. Nanotechnology offers a new way forward. Nanomaterials produce more eco-friendly, rapid, and portable diagnostic systems. They also exhibit high sensitivity and selectivity while achieving a low detection limit (LOD). This paper reviews state-of-the-art nanomaterial-based biosensors for AIV detection, such as those composed of quantum dots, gold, silver, carbon, silica, nanodiamond, and other nanoparticles. It also offers insight into potential trial protocols for creating more effective methods of identifying AIV and discusses key issues associated with developing nanomaterial-based biosensors.
Collapse
Affiliation(s)
- Wesley Wei-Wen Hsiao
- Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei, 10607, Taiwan.
| | - Gianna Fadhilah
- Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei, 10607, Taiwan
| | - Cheng-Chung Lee
- The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan
| | - Ryu Endo
- Department of Biomedical Engineering, The Ohio State University, 43210, USA
| | - Yu-Jou Lin
- Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei, 10607, Taiwan
| | - Stefanny Angela
- Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei, 10607, Taiwan
| | - Chia-Chi Ku
- Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan
| | - Huan-Cheng Chang
- Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei, 10607, Taiwan; Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei, 106319, Taiwan
| | - Wei-Hung Chiang
- Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei, 10607, Taiwan.
| |
Collapse
|
4
|
Lin HH, Wang CY, Hsieh FJ, Liao FZ, Su YK, Pham MD, Lee CY, Chang HC, Hsu HH. Nanodiamonds-in-oil emulsions elicit potent immune responses for effective vaccination and therapeutics. Nanomedicine (Lond) 2023; 18:1045-1059. [PMID: 37610004 DOI: 10.2217/nnm-2023-0179] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/24/2023] Open
Abstract
Background: The use of nanodiamonds (NDs) and fluorescent nanodiamonds (FNDs) as nonallergenic biocompatible additives in incomplete Freund's adjuvant (IFA) to elicit immune responses in vivo was investigated. Methods: C57BL/6 mice were immunized with chicken egg ovalbumin (OVA) in IFA and also OVA-conjugated NDs (or OVA-conjugated FNDs) in IFA to produce antibodies. OVA-expressing E.G7 lymphoma cells and OVA-negative EL4 cells were inoculated in mice to induce tumor formation. Results: The new formulation significantly enhanced immune responses and thus disease resistance. It exhibited specific therapeutic activities, effectively inhibiting the growth of E.G7 tumor cells in mice over 35 days. Conclusion: The high biocompatibility and multiple functionalities of NDs/FNDs render them applicable as active and trackable vaccine adjuvants and antitumor agents.
Collapse
Affiliation(s)
- Hsin-Hung Lin
- Institute of Atomic & Molecular Sciences, Academia Sinica, Taipei 106, Taiwan
| | - Chih-Yen Wang
- Institute of Atomic & Molecular Sciences, Academia Sinica, Taipei 106, Taiwan
| | - Feng-Jen Hsieh
- Institute of Atomic & Molecular Sciences, Academia Sinica, Taipei 106, Taiwan
| | - Fang-Zhen Liao
- Institute of Atomic & Molecular Sciences, Academia Sinica, Taipei 106, Taiwan
| | - Yu-Kai Su
- Institute of Atomic & Molecular Sciences, Academia Sinica, Taipei 106, Taiwan
| | - Minh Dinh Pham
- Institute of Biotechnology, Vietnam Academy of Science & Technology, Ha Noi 100000, Vietnam
| | - Chih-Yuan Lee
- Department of Surgery, National Taiwan University Hospital & College of Medicine, National Taiwan University, Taipei 100, Taiwan
| | - Huan-Cheng Chang
- Institute of Atomic & Molecular Sciences, Academia Sinica, Taipei 106, Taiwan
- Department of Chemical Engineering, National Taiwan University of Science & Technology, Taipei City 106, Taiwan
- Department of Chemistry, National Taiwan Normal University, Taipei City 106, Taiwan
| | - Hsao-Hsun Hsu
- Department of Surgery, National Taiwan University Hospital & College of Medicine, National Taiwan University, Taipei 100, Taiwan
- National Taiwan University Cancer Center, National Taiwan University, Taipei 106, Taiwan
| |
Collapse
|
5
|
Leung HM, Chu HC, Mao ZW, Lo PK. Versatile nanodiamond-based tools for therapeutics and bioimaging. Chem Commun (Camb) 2023; 59:2039-2055. [PMID: 36723092 DOI: 10.1039/d2cc06495b] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Nanodiamonds (NDs) are a remarkable class of carbon-based nanoparticles in nanomedicine which have recently become a hot topic of research due to their unique features including functionalization versatility, tunable opto-magnetic properties, chemical stability, minimal cytotoxicity, high affinity to biomolecules and biocompatibility. These attractive features make NDs versatile tools for a wide range of biologically relevant applications. In this feature article, we discuss the opto-magnetic properties of negatively charged nitrogen vacancy (NV-) centres in NDs as fluorescence probes. We further discuss the frequently used chemical methods for surface chemistry modification of NDs which are relevant for biomedical applications. The in vitro and in vivo biocompatibility of modified NDs is also highlighted. Subsequently, we give an overview of recent state-of-the-art biomedical applications of NDs as versatile tools for bioimaging and detection, and as targeting nanocarriers for chemotherapy, photodynamic therapy, gene therapy, antimicrobial and antiviral therapy, and bone tissue engineering. Finally, we pinpoint the main challenges for NDs in biomedical applications which lie ahead and discuss perspectives on future directions in advancing the field for practical applications and clinical translations.
Collapse
Affiliation(s)
- Hoi Man Leung
- Department of Chemistry and State Key Laboratory of Marine Pollution, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR, China.
| | - Hoi Ching Chu
- Department of Chemistry and State Key Laboratory of Marine Pollution, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR, China.
| | - Zheng-Wei Mao
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, P. R. China
| | - Pik Kwan Lo
- Department of Chemistry and State Key Laboratory of Marine Pollution, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR, China. .,Key Laboratory of Biochip Technology, Biotech and Health Centre, Shenzhen Research Institute of City University of Hong Kong, Shenzhen 518057, China
| |
Collapse
|
6
|
Xiao J, Sun Q, Ran L, Wang Y, Qin X, Xu X, Tang C, Liu L, Zhang G. pH-Responsive Selenium Nanoplatform for Highly Efficient Cancer Starvation Therapy by Atorvastatin Delivery. ACS Biomater Sci Eng 2023; 9:809-820. [PMID: 36622161 DOI: 10.1021/acsbiomaterials.2c01500] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Recently, starvation-inducing nutrient deprivation has been regarded as a promising strategy for tumor suppression. As a first-line lipid-lowering drug, atorvastatin (ATV) significantly reduces caloric intake, suggesting its potential in starvation therapy for suppressing tumors. Accordingly, we developed a novel starvation therapy agent (HA-Se-ATV) in this study to suppress tumor growth by using hyaluronic acid (HA)-conjugated chitosan polymer-coated nano-selenium (Se) for loading ATV. HA-Se-ATV targets cancer cells, following which it effectively accumulates in the tumor tissue. The HA-Se-ATV nanoplatform was then activated by inducing a weakly acidic tumor microenvironment and subsequently releasing ATV. ATV and Se synergistically downregulate the levels of cellular adenosine triphosphate while inhibiting the expression of thioredoxin reductase 1. Consequently, the starvation-stress reaction of cancer cells is significantly elevated, leading to cancer cell death. Furthermore, the in vivo results indicate that HA-Se-ATV effectively suppresses tumor growth with a low level of toxicity, demonstrating its great potential for clinical translation.
Collapse
Affiliation(s)
- Jianmin Xiao
- School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai264003, P. R. China
| | - Qiong Sun
- Department of Stomatology, PLA Strategic Support Force Medical Center, Beijing100101, China
| | - Lang Ran
- School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai264003, P. R. China
| | - Yinfeng Wang
- School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai264003, P. R. China
| | - Xia Qin
- School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai264003, P. R. China
| | - Xiaotong Xu
- School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai264003, P. R. China
| | - Chuhua Tang
- Department of Stomatology, PLA Strategic Support Force Medical Center, Beijing100101, China
| | - Lu Liu
- School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai264003, P. R. China
| | - Guilong Zhang
- School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai264003, P. R. China
| |
Collapse
|
7
|
Hsiao WW, Le T, Chang H. Applications of Fluorescent Nanodiamond in Biology. ENCYCLOPEDIA OF ANALYTICAL CHEMISTRY 2022:1-43. [DOI: 10.1002/9780470027318.a9776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/27/2024]
Abstract
Abstract
Fluorescent nanodiamond (FND) has emerged as a promising material in several multidisciplinary areas, including biology, chemistry, physics, and materials science. Composed of sp
3
‐carbon atoms, FND offers superior biocompatibility, chemical inertness, a large surface area, tunable surface structure, and excellent mechanical characteristics. The nanoparticle is unique in that it comprises a high‐density ensemble of negatively charged nitrogen‐vacancy (NV
−
) centers that act as built‐in fluorophores and exhibit a number of remarkable optical and magnetic properties. These properties make FND particularly well suited for a wide range of applications, including cell labeling, long‐term cell tracking, super‐resolution imaging, nanoscale sensing, and drug delivery. This article discusses recent applications of FND‐enabled developments in biology.
Collapse
|
8
|
Durán-Lobato M, López-Estévez AM, Cordeiro AS, Dacoba TG, Crecente-Campo J, Torres D, Alonso MJ. Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape. Adv Drug Deliv Rev 2021; 176:113899. [PMID: 34314784 DOI: 10.1016/j.addr.2021.113899] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2021] [Revised: 07/05/2021] [Accepted: 07/23/2021] [Indexed: 12/12/2022]
Abstract
Biological macromolecule-based therapeutics irrupted in the pharmaceutical scene generating a great hope due to their outstanding specificity and potency. However, given their susceptibility to degradation and limited capacity to overcome biological barriers new delivery technologies had to be developed for them to reach their targets. This review aims at analyzing the historical seminal advances that shaped the development of the protein/peptide delivery field, along with the emerging technologies on the lead of the current landscape. Particularly, focus is made on technologies with a potential for transmucosal systemic delivery of protein/peptide drugs, followed by approaches for the delivery of antigens as new vaccination strategies, and formulations of biological drugs in oncology, with special emphasis on mAbs. Finally, a discussion of the key challenges the field is facing, along with an overview of prospective advances are provided.
Collapse
|
9
|
Producing Vaccines against Enveloped Viruses in Plants: Making the Impossible, Difficult. Vaccines (Basel) 2021; 9:vaccines9070780. [PMID: 34358196 PMCID: PMC8310165 DOI: 10.3390/vaccines9070780] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Revised: 07/07/2021] [Accepted: 07/08/2021] [Indexed: 12/13/2022] Open
Abstract
The past 30 years have seen the growth of plant molecular farming as an approach to the production of recombinant proteins for pharmaceutical and biotechnological uses. Much of this effort has focused on producing vaccine candidates against viral diseases, including those caused by enveloped viruses. These represent a particular challenge given the difficulties associated with expressing and purifying membrane-bound proteins and achieving correct assembly. Despite this, there have been notable successes both from a biochemical and a clinical perspective, with a number of clinical trials showing great promise. This review will explore the history and current status of plant-produced vaccine candidates against enveloped viruses to date, with a particular focus on virus-like particles (VLPs), which mimic authentic virus structures but do not contain infectious genetic material.
Collapse
|
10
|
Bilyy R, Pagneux Q, François N, Bila G, Grytsko R, Lebedin Y, Barras A, Dubuisson J, Belouzard S, Séron K, Boukherroub R, Szunerits S. Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds. Pathogens 2021; 10:861. [PMID: 34358011 PMCID: PMC8308543 DOI: 10.3390/pathogens10070861] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 06/27/2021] [Accepted: 06/28/2021] [Indexed: 12/29/2022] Open
Abstract
Vaccination remains one of the most effective tools to prevent infectious diseases. To ensure that the best possible antigenic components are chosen to stimulate a cognitive immune response, boosting antigen presentation using adjuvants is common practice. Nanodiamond-based adjuvants are proposed here as a rapid and versatile platform for antigen conjugation, utilizing peptides common to different pathogenic strains and making this strategy a good candidate for a "ready-to-use" vaccine. Initiation of an inflammatory reaction with a resulting immune response is based on the ability of living organisms to entrap nanostructures such as nanodiamonds with neutrophil extracellular traps (NETs) formation. In this work, coronavirus peptide homological for MERS-CoV, fusion inhibitor, was conjugated to nanodiamonds and used to induce neutrophilic-driven self-limiting inflammation. The resulting adjuvant was safe and did not induce any tissue damage at the site of injection. Mice immunization resulted in IgG titers of ¼,000 within 28 days. Immunization of rabbits resulted in the formation of a high level of antibodies persistently present for up to 120 days after the first immunization (animal lifespan ~3 years). The peptide used for immunization proved to be reactive with sera of convalescent COVID patients, demonstrating the possibility of developing pancoronaviral vaccine candidates.
Collapse
Affiliation(s)
- Rostyslav Bilyy
- Danylo Halytsky Lviv National Medical University, Pekarska Str., 69, 79010 Lviv, Ukraine; (G.B.); (R.G.)
| | - Quentin Pagneux
- University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France; (Q.P.); (A.B.); (R.B.)
| | - Nathan François
- U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France; (N.F.); (J.D.); (S.B.); (K.S.)
| | - Galyna Bila
- Danylo Halytsky Lviv National Medical University, Pekarska Str., 69, 79010 Lviv, Ukraine; (G.B.); (R.G.)
| | - Roman Grytsko
- Danylo Halytsky Lviv National Medical University, Pekarska Str., 69, 79010 Lviv, Ukraine; (G.B.); (R.G.)
| | - Yuri Lebedin
- Xema Co., Ltd., Akademika Efremova Str., 23, 03179 Kyiv, Ukraine;
| | - Alexandre Barras
- University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France; (Q.P.); (A.B.); (R.B.)
| | - Jean Dubuisson
- U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France; (N.F.); (J.D.); (S.B.); (K.S.)
| | - Sandrine Belouzard
- U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France; (N.F.); (J.D.); (S.B.); (K.S.)
| | - Karin Séron
- U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France; (N.F.); (J.D.); (S.B.); (K.S.)
| | - Rabah Boukherroub
- University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France; (Q.P.); (A.B.); (R.B.)
| | - Sabine Szunerits
- University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France; (Q.P.); (A.B.); (R.B.)
| |
Collapse
|
11
|
Venkataraman S, Hefferon K, Makhzoum A, Abouhaidar M. Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer? Vaccines (Basel) 2021; 9:vaccines9070761. [PMID: 34358177 PMCID: PMC8310141 DOI: 10.3390/vaccines9070761] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 07/02/2021] [Accepted: 07/04/2021] [Indexed: 12/28/2022] Open
Abstract
Molecular pharming or the technology of application of plants and plant cell culture to manufacture high-value recombinant proteins has progressed a long way over the last three decades. Whether generated in transgenic plants by stable expression or in plant virus-based transient expression systems, biopharmaceuticals have been produced to combat several human viral diseases that have impacted the world in pandemic proportions. Plants have been variously employed in expressing a host of viral antigens as well as monoclonal antibodies. Many of these biopharmaceuticals have shown great promise in animal models and several of them have performed successfully in clinical trials. The current review elaborates the strategies and successes achieved in generating plant-derived vaccines to target several virus-induced health concerns including highly communicable infectious viral diseases. Importantly, plant-made biopharmaceuticals against hepatitis B virus (HBV), hepatitis C virus (HCV), the cancer-causing virus human papillomavirus (HPV), human immunodeficiency virus (HIV), influenza virus, zika virus, and the emerging respiratory virus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been discussed. The use of plant virus-derived nanoparticles (VNPs) and virus-like particles (VLPs) in generating plant-based vaccines are extensively addressed. The review closes with a critical look at the caveats of plant-based molecular pharming and future prospects towards further advancements in this technology. The use of biopharmed viral vaccines in human medicine and as part of emergency response vaccines and therapeutics in humans looks promising for the near future.
Collapse
Affiliation(s)
- Srividhya Venkataraman
- Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada; (K.H.); (M.A.)
- Correspondence:
| | - Kathleen Hefferon
- Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada; (K.H.); (M.A.)
| | - Abdullah Makhzoum
- Department of Biological Sciences & Biotechnology, Botswana International University of Science & Technology, Palapye, Botswana;
| | - Mounir Abouhaidar
- Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada; (K.H.); (M.A.)
| |
Collapse
|
12
|
Ho TT, Pham VT, Nguyen TT, Trinh VT, Vi T, Lin HH, Nguyen PMT, Bui HT, Pham NB, Le TBT, Phan CV, Chang HC, Hsiao WWW, Chu HH, Pham MD. Effects of Size and Surface Properties of Nanodiamonds on the Immunogenicity of Plant-Based H5 Protein of A/H5N1 Virus in Mice. NANOMATERIALS 2021; 11:nano11061597. [PMID: 34204514 PMCID: PMC8234943 DOI: 10.3390/nano11061597] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/21/2021] [Revised: 06/04/2021] [Accepted: 06/15/2021] [Indexed: 12/18/2022]
Abstract
Nanodiamond (ND) has recently emerged as a potential nanomaterial for nanovaccine development. Here, a plant-based haemagglutinin protein (H5.c2) of A/H5N1 virus was conjugated with detonation NDs (DND) of 3.7 nm in diameter (ND4), and high-pressure and high-temperature (HPHT) oxidative NDs of ~40-70 nm (ND40) and ~100-250 nm (ND100) in diameter. Our results revealed that the surface charge, but not the size of NDs, is crucial to the protein conjugation, as well as the in vitro and in vivo behaviors of H5.c2:ND conjugates. Positively charged ND4 does not effectively form stable conjugates with H5.c2, and has no impact on the immunogenicity of the protein both in vitro and in vivo. In contrast, the negatively oxidized NDs (ND40 and ND100) are excellent protein antigen carriers. When compared to free H5.c2, H5.c2:ND40, and H5.c2:ND100 conjugates are highly immunogenic with hemagglutination titers that are both 16 times higher than that of the free H5.c2 protein. Notably, H5.c2:ND40 and H5.c2:ND100 conjugates induce over 3-folds stronger production of both H5.c2-specific-IgG and neutralizing antibodies against A/H5N1 than free H5.c2 in mice. These findings support the innovative strategy of using negatively oxidized ND particles as novel antigen carriers for vaccine development, while also highlighting the importance of particle characterization before use.
Collapse
Affiliation(s)
- Thuong Thi Ho
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
- Faculty of Biotechnology, Graduate University of Science and Technology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam
| | - Van Thi Pham
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
- Faculty of Biotechnology, Graduate University of Science and Technology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam
| | - Tra Thi Nguyen
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
- Faculty of Biotechnology, Graduate University of Science and Technology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam
| | - Vy Thai Trinh
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
- Faculty of Biotechnology, Graduate University of Science and Technology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam
| | - Tram Vi
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
- Faculty of Medical Biotechnology—Plant Biotechnology—Pharmacology, University of Science and Technology of Hanoi (USTH), 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam
| | - Hsin-Hung Lin
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei 10617, Taiwan; (H.-H.L.); (H.-C.C.)
| | - Phuong Minh Thi Nguyen
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
| | - Huyen Thi Bui
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
| | - Ngoc Bich Pham
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
- Faculty of Biotechnology, Graduate University of Science and Technology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam
| | - Thao Bich Thi Le
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
| | - Chi Van Phan
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
| | - Huan-Cheng Chang
- Institute of Atomic and Molecular Sciences, Academia Sinica, Taipei 10617, Taiwan; (H.-H.L.); (H.-C.C.)
| | - Wesley Wei-Wen Hsiao
- Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei 106335, Taiwan;
| | - Ha Hoang Chu
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
- Faculty of Biotechnology, Graduate University of Science and Technology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam
- Correspondence: (H.H.C.); (M.D.P.)
| | - Minh Dinh Pham
- Institute of Biotechnology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam; (T.T.H.); (V.T.P.); (T.T.N.); (V.T.T.); (T.V.); (P.M.T.N.); (H.T.B.); (N.B.P.); (T.B.T.L.); (C.V.P.)
- Faculty of Biotechnology, Graduate University of Science and Technology, Vietnam Academy of Science and Technology, 18-Hoang Quoc Viet, Cau Giay, Hanoi 100000, Vietnam
- Correspondence: (H.H.C.); (M.D.P.)
| |
Collapse
|
13
|
Abstract
The host immune system is highly compromised in case of viral infections and relapses are very common. The capacity of the virus to destroy the host cell by liberating its own DNA or RNA and replicating inside the host cell poses challenges in the development of antiviral therapeutics. In recent years, many new technologies have been explored for diagnosis, prevention, and treatment of viral infections. Nanotechnology has emerged as one of the most promising technologies on account of its ability to deal with viral diseases in an effective manner, addressing the limitations of traditional antiviral medicines. It has not only helped us to overcome problems related to solubility and toxicity of drugs, but also imparted unique properties to drugs, which in turn has increased their potency and selectivity toward viral cells against the host cells. The initial part of the paper focuses on some important proteins of influenza, Ebola, HIV, herpes, Zika, dengue, and corona virus and those of the host cells important for their entry and replication into the host cells. This is followed by different types of nanomaterials which have served as delivery vehicles for the antiviral drugs. It includes various lipid-based, polymer-based, lipid-polymer hybrid-based, carbon-based, inorganic metal-based, surface-modified, and stimuli-sensitive nanomaterials and their application in antiviral therapeutics. The authors also highlight newer promising treatment approaches like nanotraps, nanorobots, nanobubbles, nanofibers, nanodiamonds, nanovaccines, and mathematical modeling for the future. The paper has been updated with the recent developments in nanotechnology-based approaches in view of the ongoing pandemic of COVID-19.Graphical abstract.
Collapse
Affiliation(s)
- Malobika Chakravarty
- Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai, 400056, India
| | - Amisha Vora
- Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai, 400056, India.
| |
Collapse
|
14
|
Suarez-Kelly L, Sun SH, Ren C, Rampersaud IV, Albertson D, Duggan MC, Noel TC, Courtney N, Buteyn NJ, Moritz C, Yu L, Yildiz VO, Butchar JP, Tridandapani S, Rampersaud AA, Carson WE. Antibody Conjugation of Fluorescent Nanodiamonds for Targeted Innate Immune Cell Activation. ACS APPLIED NANO MATERIALS 2021; 4:3122-3139. [PMID: 34027313 PMCID: PMC8136585 DOI: 10.1021/acsanm.1c00256] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
BACKGROUND fluorescent nanodiamonds (FND) are nontoxic, infinitely photostable nanoparticles that emit near-infrared fluorescence and have a modifiable surface allowing for the generation of protein-FND conjugates. FND-mediated immune cell targeting may serve as a strategy to visualize immune cells and promote immune cell activation. METHODS uncoated-FND (uFND) were fabricated, coated with glycidol (gFND), and conjugated with immunoglobulin G (IgG-gFND). In vitro studies were performed using a breast cancer/natural killer/monocyte co-culture system, and in vivo studies were performed using a breast cancer mouse model. RESULTS in vitro studies demonstrated the targeted immune cell uptake of IgG-gFND, resulting in significant immune cell activation and no compromise in immune cell viability. IgG-gFND remained at the tumor site following intratumoral injection compared to uFND which migrated to the liver and kidneys. CONCLUSION antibody-conjugated FND may serve as immune drug delivery vehicles with "track and trace capabilities" to promote directed antitumor activity and minimize systemic toxicities.
Collapse
Affiliation(s)
- Lorena
P. Suarez-Kelly
- The
Arthur G. James Comprehensive Cancer Center and Solove Research Institute, The Ohio State University, Columbus, Ohio 43210, United States
| | - Steven H. Sun
- Department
of Surgery, The Ohio State University, Columbus, Ohio 43210, United States
| | - Casey Ren
- The
Arthur G. James Comprehensive Cancer Center and Solove Research Institute, The Ohio State University, Columbus, Ohio 43210, United States
| | - Isaac V. Rampersaud
- Columbus
NanoWorks, Inc., 1507
Chambers Road, Columbus, Ohio 43212, United
States
| | - David Albertson
- Columbus
NanoWorks, Inc., 1507
Chambers Road, Columbus, Ohio 43212, United
States
| | - Megan C. Duggan
- The
Arthur G. James Comprehensive Cancer Center and Solove Research Institute, The Ohio State University, Columbus, Ohio 43210, United States
| | - Tiffany C. Noel
- The
Arthur G. James Comprehensive Cancer Center and Solove Research Institute, The Ohio State University, Columbus, Ohio 43210, United States
| | - Nicholas Courtney
- The
Arthur G. James Comprehensive Cancer Center and Solove Research Institute, The Ohio State University, Columbus, Ohio 43210, United States
| | - Nathaniel J. Buteyn
- Division
of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department
of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, United States
| | - Charles Moritz
- Columbus
NanoWorks, Inc., 1507
Chambers Road, Columbus, Ohio 43212, United
States
| | - Lianbo Yu
- Department
of Biomedical Informatics, The Ohio State
University, Columbus, Ohio 43210, United States
| | - Vedat O. Yildiz
- Department
of Biomedical Informatics, The Ohio State
University, Columbus, Ohio 43210, United States
| | - Jonathan P. Butchar
- Division
of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department
of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, United States
| | - Susheela Tridandapani
- Division
of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department
of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, United States
| | - Arfaan A. Rampersaud
- Columbus
NanoWorks, Inc., 1507
Chambers Road, Columbus, Ohio 43212, United
States
| | - William E. Carson
- The
Arthur G. James Comprehensive Cancer Center and Solove Research Institute, The Ohio State University, Columbus, Ohio 43210, United States
- Department
of Surgery, The Ohio State University, Columbus, Ohio 43210, United States
- . Phone: (614)
293-6306. Fax: (614) 293-3465
| |
Collapse
|
15
|
Ho TT, Nguyen GT, Pham NB, Le VP, Trinh TBN, Vu TH, Phan HT, Conrad U, Chu HH. Plant-Derived Trimeric CO-26K-Equivalent Epitope Induced Neutralizing Antibodies Against Porcine Epidemic Diarrhea Virus. Front Immunol 2020; 11:2152. [PMID: 33042128 PMCID: PMC7524870 DOI: 10.3389/fimmu.2020.02152] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Accepted: 08/07/2020] [Indexed: 12/30/2022] Open
Abstract
Porcine epidemic diarrhea virus (PEDV) is a causative agent of a highly infectious disease with a high mortality rate, especially in newborn piglets in Asian countries resulting in serious economic loss. The development of a rapid, safe, effective and cost-efficient vaccine is crucial to protect pigs against PEDV infection. The COE antigen is regarded to be a major target for subunit vaccine development against PEDV infection. The naturally assembled COE protein forms a homotrimeric structure. In the present study, we successfully produced a trimeric COE protein as a native structure by fusion with the C-terminal isoleucine zipper trimerization (GCN4pII) motif in Nicotiana benthamiana, with a high expression level shown via semi-quantified Western blots. Trimeric COE protein was purified via immobilized metal affinity chromatography (IMAC), and its trimeric structure was successfully demonstrated by a cross-linking reaction, and a native PAGE gel. A crude extract containing the COE trimer was used for evaluating immunogenicity in mice. After 1 and 2 booster immunizations, the crude extract containing trimeric COE elicited elevated PEDV-specific humoral responses, as demonstrated by ELISA and Western blot analyses. Notably, a virus-neutralizing antibody assay indicated that the neutralization activities of sera of mice vaccinated with the crude extract containing COE-GCN4pII were similar to those of mice vaccinated with a commercial vaccine. These results suggest that crude extract containing trimeric COE is a promising plant-based subunit vaccine candidate for PEDV prevention.
Collapse
Affiliation(s)
- Thuong Thi Ho
- Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Ha Noi, Vietnam
- Institute of Biotechnology, Vietnam Academy of Science and Technology, Ha Noi, Vietnam
| | - Giang Thu Nguyen
- Institute of Biotechnology, Vietnam Academy of Science and Technology, Ha Noi, Vietnam
| | - Ngoc Bich Pham
- Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Ha Noi, Vietnam
- Institute of Biotechnology, Vietnam Academy of Science and Technology, Ha Noi, Vietnam
| | - Van Phan Le
- Vietnam National University of Agriculture, Ha Noi, Vietnam
| | | | - Trang Huyen Vu
- Institute of Biotechnology, Vietnam Academy of Science and Technology, Ha Noi, Vietnam
| | - Hoang Trong Phan
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Gatersleben, Germany
| | - Udo Conrad
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Gatersleben, Germany
| | - Ha Hoang Chu
- Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Ha Noi, Vietnam
- Institute of Biotechnology, Vietnam Academy of Science and Technology, Ha Noi, Vietnam
| |
Collapse
|
16
|
Reina G, Peng S, Jacquemin L, Andrade AF, Bianco A. Hard Nanomaterials in Time of Viral Pandemics. ACS NANO 2020; 14:9364-9388. [PMID: 32667191 PMCID: PMC7376974 DOI: 10.1021/acsnano.0c04117] [Citation(s) in RCA: 55] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Accepted: 07/15/2020] [Indexed: 05/05/2023]
Abstract
The SARS-Cov-2 pandemic has spread worldwide during 2020, setting up an uncertain start of this decade. The measures to contain infection taken by many governments have been extremely severe by imposing home lockdown and industrial production shutdown, making this the biggest crisis since the second world war. Additionally, the continuous colonization of wild natural lands may touch unknown virus reservoirs, causing the spread of epidemics. Apart from SARS-Cov-2, the recent history has seen the spread of several viral pandemics such as H2N2 and H3N3 flu, HIV, and SARS, while MERS and Ebola viruses are considered still in a prepandemic phase. Hard nanomaterials (HNMs) have been recently used as antimicrobial agents, potentially being next-generation drugs to fight viral infections. HNMs can block infection at early (disinfection, entrance inhibition) and middle (inside the host cells) stages and are also able to mitigate the immune response. This review is focused on the application of HNMs as antiviral agents. In particular, mechanisms of actions, biological outputs, and limitations for each HNM will be systematically presented and analyzed from a material chemistry point-of-view. The antiviral activity will be discussed in the context of the different pandemic viruses. We acknowledge that HNM antiviral research is still at its early stage, however, we believe that this field will rapidly blossom in the next period.
Collapse
Affiliation(s)
- Giacomo Reina
- CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572,
University of Strasbourg ISIS, 67000 Strasbourg,
France
| | - Shiyuan Peng
- CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572,
University of Strasbourg ISIS, 67000 Strasbourg,
France
| | - Lucas Jacquemin
- CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572,
University of Strasbourg ISIS, 67000 Strasbourg,
France
| | - Andrés Felipe Andrade
- CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572,
University of Strasbourg ISIS, 67000 Strasbourg,
France
| | - Alberto Bianco
- CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572,
University of Strasbourg ISIS, 67000 Strasbourg,
France
| |
Collapse
|
17
|
Pushko P, Tretyakova I. Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development. Viruses 2020; 12:v12050518. [PMID: 32397182 PMCID: PMC7291233 DOI: 10.3390/v12050518] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 04/21/2020] [Accepted: 04/27/2020] [Indexed: 01/21/2023] Open
Abstract
In the midst of the ongoing COVID-19 coronavirus pandemic, influenza virus remains a major threat to public health due to its potential to cause epidemics and pandemics with significant human mortality. Cases of H7N9 human infections emerged in eastern China in 2013 and immediately raised pandemic concerns as historically, pandemics were caused by the introduction of new subtypes into immunologically naïve human populations. Highly pathogenic H7N9 cases with severe disease were reported recently, indicating the continuing public health threat and the need for a prophylactic vaccine. Here we review the development of recombinant influenza virus-like particles (VLPs) as vaccines against H7N9 virus. Several approaches to vaccine development are reviewed including the expression of VLPs in mammalian, plant and insect cell expression systems. Although considerable progress has been achieved, including demonstration of safety and immunogenicity of H7N9 VLPs in the human clinical trials, the remaining challenges need to be addressed. These challenges include improvements to the manufacturing processes, as well as enhancements to immunogenicity in order to elicit protective immunity to multiple variants and subtypes of influenza virus.
Collapse
|
18
|
Bhardwaj P, Bhatia E, Sharma S, Ahamad N, Banerjee R. Advancements in prophylactic and therapeutic nanovaccines. Acta Biomater 2020; 108:1-21. [PMID: 32268235 PMCID: PMC7163188 DOI: 10.1016/j.actbio.2020.03.020] [Citation(s) in RCA: 75] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Revised: 03/13/2020] [Accepted: 03/17/2020] [Indexed: 02/07/2023]
Abstract
Vaccines activate suitable immune responses to fight against diseases but can possess limitations such as compromised efficacy and immunogenic responses, poor stability, and requirement of adherence to multiple doses. ‘Nanovaccines’ have been explored to elicit a strong immune response with the advantages of nano-sized range, high antigen loading, enhanced immunogenicity, controlled antigen presentation, more retention in lymph nodes and promote patient compliance by a lower frequency of dosing. Various types of nanoparticles with diverse pathogenic or foreign antigens can help to overcome immunotolerance and alleviate the need of booster doses as required with conventional vaccines. Nanovaccines have the potential to induce both cell-mediated and antibody-mediated immunity and can render long-lasting immunogenic memory. With such properties, nanovaccines have shown high potential for the prevention of infectious diseases such as acquired immunodeficiency syndrome (AIDS), malaria, tuberculosis, influenza, and cancer. Their therapeutic potential has also been explored in the treatment of cancer. The various kinds of nanomaterials used for vaccine development and their effects on immune system activation have been discussed with special relevance to their implications in various pathological conditions. Statement of Significance Interaction of nanoparticles with the immune system has opened multiple avenues to combat a variety of infectious and non-infectious pathological conditions. Limitations of conventional vaccines have paved the path for nanomedicine associated benefits with a hope of producing effective nanovaccines. This review highlights the role of different types of nanovaccines and the role of nanoparticles in modulating the immune response of vaccines. The applications of nanovaccines in infectious and non-infectious diseases like malaria, tuberculosis, AIDS, influenza, and cancers have been discussed. It will help the readers develop an understanding of mechanisms of immune activation by nanovaccines and design appropriate strategies for novel nanovaccines.
Collapse
|
19
|
Shen D, Zhu L, Liu Y, Peng Y, Lan M, Fang K, Guo Y. Efficacy evaluation and mechanism study on inhibition of breast cancer cell growth by multimodal targeted nanobubbles carrying AMD070 and ICG. NANOTECHNOLOGY 2020; 31:245102. [PMID: 32155591 DOI: 10.1088/1361-6528/ab7e73] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
To construct targeted nanobubbles carrying both small-molecule CXCR4 antagonist AMD070 and light-absorbing material indocyanine green (ICG), and to study their in vitro multimodal imaging, as well as their mechanism and efficacy of inhibition of breast cancer cell growth. Nanobubbles carrying AMD070 and ICG (ICG-TNBs) were constructed by carbodiimide reaction and mechanical oscillation. The physical characteristics and in vitro multimodal imaging were determined. The binding potential of ICG-TNBs to human breast cancer cells were observed by laser confocal microscopy. CCK-8 and flow cytometry were used to analyze the role of ICG-TNBs + US in inhibiting proliferation and inducing apoptosis of tumor cells. Flow cytometry and Western blotting are used to analyse the ROS generation and molecular mechanisms. ICG-TNBs had a particle size of 497.0 ± 29.2 nm and a Zeta potential of -8.05 ± 0.73 mV. In vitro multimodal imaging showed that the image signal intensity of ICG-TNBs increased with concentration. Targeted binding assay confirmed that ICG-TNBs could specifically bind to MCF-7 cells (CXCR4 positive), but not to MDA-MB-468 cells (CXCR4 negative). CCK-8 assay and flow cytometry analysis showed that ICG-TNBs + US could significantly inhibit the growth of MCF-7 breast cancer cells and promote their apoptosis. Flow cytometry and Western blotting showed that ICG-TNBs + US could significantly raise generation of ROS, reduce the expression of CXCR4, inhibit phosphorylation of Akt, and increase the expression of Caspase3 and Cleaved-caspase3. This indicated that ICG-TNBs could effectively inhibit and block the SDF-1/CXCR4 pathway, thus leading to the apoptosis of MCF-7 cells. ICG-TNBs can specifically bind to CXCR4 positive breast cancer cells, furthermore inhibit growth and promote apoptosis of breast cancer cells combined with ultrasonic irradiation by blocking the SDF-1/CXCR4 pathway. This study introduces a novel concept, method and mechanism for integration of targeted diagnosis and treatment of breast cancer.
Collapse
Affiliation(s)
- Daijia Shen
- Department of Ultrasound, Southwest Hospital, Third Military Medical University (Army Medical University), 30 Gaotanyan Street, Shapingba District, Chongqing 400038, People's Republic of China
| | | | | | | | | | | | | |
Collapse
|
20
|
Raguraman V, Suthindhiran K. Comparative ecotoxicity assessment of magnetosomes and magnetite nanoparticles. INTERNATIONAL JOURNAL OF ENVIRONMENTAL HEALTH RESEARCH 2020; 30:13-25. [PMID: 30714827 DOI: 10.1080/09603123.2019.1570489] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Accepted: 01/12/2019] [Indexed: 06/09/2023]
Abstract
Magnetite nanoparticles (MNPs) are gaining attention because of their biomedical, environmental and industrial applications. However, they have limited uses because of ecotoxicity. On contrast, bacterially synthesized MNPs such as magnetosomes are found to be biocompatible and less toxic due to the lipid bilayer membrane found around magnetite. In this context, this study compares the physio-chemical properties and toxicology effects of MNPs and magnetosomes in different models such as human red blood cells, macrophage cell lines (RAW 264.7), onion root tips (Allium cepa), Artemia salina (A. salina) and zebrafish embryo (Danio rerio). MNPs showed 38.59% hemolysis whereas the maximum hemolysis induced by magnetosomes was 7.03% for the same concentration (250 μg/ml). The cytotoxicity of MNPs and magnetosomes were 36.01% and 13.4%, respectively, at 250 μg/ml. Onion root tip assay revealed high toxicity when treated with MNPs than magnetosomes. The MNPs were further tested for its toxicity against A. salina and 50% mortality rate was observed. Similarly, notable malformation was seen in zebrafish embryo treated with MNPs. However, magnetosomes did not exhibit any mortality and malformation in A. salina and zebrafish embryo. The study revealed that magnetosomes are safe and do not cause any potential risk to environment compared to synthetic MNPs.Abbreviation: MNPs: Magnetic nanoparticles; ATCC: American Type Culture Collection; MTB: Magnetotactic bacteria; MSR-1: Magnetospirillum gryphiswaldense; DSMZ: Deutsche Sammlung von Mikroorganismen und Zellkulturen; MSGM: Magnetospirillum growth medium; D-PBS: Dulbecco phosphate buffer saline; RBC: Red blood cells; SEM: Scanning electron microscopy; HRTEM: High-resolution transition electron microscope; FTIR: Fourier transform infrared spectroscopy; XRD: X-ray powder diffraction; AFM: Atomic-force microscopy; ZP: Zeta Potential; PSD: Particle Size Distribution; EDX: Energy-dispersive X-ray spectroscopy; PBS: Phosphate buffer saline; DMEM: Dulbecco's modified eagle medium; HEPES: (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); MTT:3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; DMSO: Dimethyl sulfoxide; ROS: Reactive oxygen species.
Collapse
Affiliation(s)
- Varalakshmi Raguraman
- Marine Biotechnology and Bioproducts Laboratory, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, India
| | - K Suthindhiran
- Marine Biotechnology and Bioproducts Laboratory, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, India
| |
Collapse
|
21
|
Křivohlavá R, Neuhӧferová E, Jakobsen KQ, Benson V. Knockdown of microRNA-135b in Mammary Carcinoma by Targeted Nanodiamonds: Potentials and Pitfalls of In Vivo Applications. NANOMATERIALS 2019; 9:nano9060866. [PMID: 31181619 PMCID: PMC6632128 DOI: 10.3390/nano9060866] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 06/03/2019] [Accepted: 06/04/2019] [Indexed: 12/26/2022]
Abstract
Nanodiamonds (ND) serve as RNA carriers with potential for in vivo application. ND coatings and their administration strategy significantly change their fate, toxicity, and effectivity within a multicellular system. Our goal was to develop multiple ND coating for effective RNA delivery in vivo. Our final complex (NDA135b) consisted of ND, polymer, antisense RNA, and transferrin. We aimed (i) to assess if a tumor-specific coating promotes NDA135b tumor accumulation and effective inhibition of oncogenic microRNA-135b and (ii) to outline off-targets and immune cell interactions. First, we tested NDA135b toxicity and effectivity in tumorospheres co-cultured with immune cells ex vivo. We found NDA135b to target tumor cells, but it binds also to granulocytes. Then, we followed with NDA135b intravenous and intratumoral applications in tumor-bearing animals in vivo. Application of NDA135b in vivo led to the effective knockdown of microRNA-135b in tumor tissue regardless administration. Only intravenous application resulted in NDA135b circulation in peripheral blood and urine and the decreased granularity of splenocytes. Our data show that localized intratumoral application of NDA135b represents a suitable and safe approach for in vivo application of nanodiamond-based constructs. Systemic intravenous application led to an interaction of NDA135b with bio-interface, and needs further examination regarding its safety.
Collapse
Affiliation(s)
- Romana Křivohlavá
- Institute of Microbiology of the CAS, v.v.i., Videnska 1083, 142 20 Prague 4, Czech Republic.
| | - Eva Neuhӧferová
- Institute of Microbiology of the CAS, v.v.i., Videnska 1083, 142 20 Prague 4, Czech Republic.
| | - Katrine Q Jakobsen
- Institute of Microbiology of the CAS, v.v.i., Videnska 1083, 142 20 Prague 4, Czech Republic.
| | - Veronika Benson
- Institute of Microbiology of the CAS, v.v.i., Videnska 1083, 142 20 Prague 4, Czech Republic.
| |
Collapse
|
22
|
Applications of Nanodiamonds in the Detection and Therapy of Infectious Diseases. MATERIALS 2019; 12:ma12101639. [PMID: 31137476 PMCID: PMC6567273 DOI: 10.3390/ma12101639] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/20/2019] [Revised: 05/14/2019] [Accepted: 05/15/2019] [Indexed: 12/14/2022]
Abstract
We are constantly exposed to infectious diseases, and they cause millions of deaths per year. The World Health Organization (WHO) estimates that antibiotic resistance could cause 10 million deaths per year by 2050. Multidrug-resistant bacteria are the cause of infection in at least one in three people suffering from septicemia. While antibiotics are powerful agents against infectious diseases, the alarming increase in antibiotic resistance is of great concern. Alternatives are desperately needed, and nanotechnology provides a great opportunity to develop novel approaches for the treatment of infectious diseases. One of the most important factors in the prognosis of an infection caused by an antibiotic resistant bacteria is an early and rigorous diagnosis, jointly with the use of novel therapeutic systems that can specifically target the pathogen and limit the selection of resistant strains. Nanodiamonds can be used as antimicrobial agents due to some of their properties including size, shape, and biocompatibility, which make them highly suitable for the development of efficient and tailored nanotherapies, including vaccines or drug delivery systems. In this review, we discuss the beneficial findings made in the nanodiamonds field, focusing on diagnosis and treatment of infectious diseases. We also highlight the innovative platform that nanodiamonds confer for vaccine improvement, drug delivery, and shuttle systems, as well as their role in the generation of faster and more sensitive clinical diagnosis.
Collapse
|
23
|
Barone FC, Marcinkiewicz C, Li J, Sternberg M, Lelkes PI, Dikin DA, Bergold PJ, Gerstenhaber JA, Feuerstein G. Pilot study on biocompatibility of fluorescent nanodiamond-(NV)-Z~800 particles in rats: safety, pharmacokinetics, and bio-distribution (part III). Int J Nanomedicine 2018; 13:5449-5468. [PMID: 30271140 PMCID: PMC6149985 DOI: 10.2147/ijn.s171117] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Introduction We hereby report on studies aimed to characterize safety, pharmacokinetics, and bio-distribution of fluorescent nanodiamond particles (NV)-Z~800 (FNDP-(NV)) administered to rats by intravenous infusion in a single high dose. Methods Broad scale biological variables were monitored following acute (90 minutes) and subacute (5 or 14 days) exposure to FNDP-(NV). Primary endpoints included morbidity and mortality, while secondary endpoints focused on hematology and clinical biochemistry biomarkers. Particle distribution (liver, spleen, lung, heart, and kidney) was assessed by whole organ near infrared imaging using an in vivo imaging system. This was validated by the quantification of particles extracted from the same organs and visualized by fluorescent and scanning electron microscopy. FNDP-(NV)-treated rats showed no change in morbidity or mortality and preserved normal motor and sensory function, as assessed by six different tests. Results Blood cell counts and plasma biochemistry remained normal. The particles were principally distributed in the liver and spleen. The liver particle load accounted for 51%, 24%, and 18% at 90 minutes, 5 days, and 14 days, respectively. A pilot study of particle clearance from blood indicated 50% clearance 33 minutes following the end of particle infusion. Conclusion We concluded that systemic exposure of rats to a single high dose of FDNP-(NV)-Z~800 (60 mg/kg) appeared to be safe and well tolerated over at least 2 weeks. These data suggest that FNDP-(NV) should proceed to preclinical development in the near future.
Collapse
Affiliation(s)
- Frank C Barone
- Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA
| | - Cezary Marcinkiewicz
- Department of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA, .,Debina Diagnostics Inc, Newtown Square, PA, USA,
| | - Jie Li
- Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA
| | | | - Peter I Lelkes
- Department of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA,
| | - Dmitriy A Dikin
- Department of Mechanical Engineering, Temple University, Philadelphia, PA, USA
| | - Peter J Bergold
- Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA
| | - Jonathan A Gerstenhaber
- Department of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA,
| | | |
Collapse
|